RecruitingPhase 4NCT01818661

Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech

Sponsor

Mayo Clinic

Enrollment

50 participants

Start Date

Jul 1, 2018

Study Type

INTERVENTIONAL

Conditions

Apraxia of Speech Primary Progressive Aphasia PPA Non-fluent Aphasia Primary Progressive Non-fluent Aphasia

Summary

The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with neurodegenerative apraxia of speech (AOS).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AV-1451 for people with apraxia of speech, non-fluent aphasia, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.